Walleye Capital LLC Invests $1.48 Million in Enliven Therapeutics, Inc. $ELVN

Walleye Capital LLC acquired a new stake in Enliven Therapeutics, Inc. (NASDAQ:ELVN) during the first quarter, HoldingsChannel reports. The fund acquired 37,827 shares of the company’s stock, valued at approximately $1,483,000.

Several other large investors have also recently added to or reduced their stakes in ELVN. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Enliven Therapeutics by 25.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,884 shares of the company’s stock valued at $44,000 after acquiring an additional 594 shares in the last quarter. Invesco Ltd. raised its stake in Enliven Therapeutics by 4.3% in the 2nd quarter. Invesco Ltd. now owns 21,957 shares of the company’s stock worth $440,000 after purchasing an additional 913 shares in the last quarter. BNP Paribas Financial Markets raised its stake in Enliven Therapeutics by 33.3% in the 2nd quarter. BNP Paribas Financial Markets now owns 3,722 shares of the company’s stock worth $75,000 after purchasing an additional 930 shares in the last quarter. KBC Group NV bought a new stake in Enliven Therapeutics in the 1st quarter valued at about $38,000. Finally, Swiss National Bank boosted its holdings in Enliven Therapeutics by 1.7% in the 4th quarter. Swiss National Bank now owns 64,273 shares of the company’s stock valued at $990,000 after purchasing an additional 1,100 shares during the period. Institutional investors own 95.08% of the company’s stock.

Insider Buying and Selling at Enliven Therapeutics

In other Enliven Therapeutics news, Director Lori Anne Kunkel sold 10,000 shares of the stock in a transaction dated Monday, July 6th. The stock was sold at an average price of $50.49, for a total transaction of $504,900.00. Following the completion of the sale, the director directly owned 41,884 shares in the company, valued at approximately $2,114,723.16. This trade represents a 19.27% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Benjamin Hohl sold 6,018 shares of Enliven Therapeutics stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $43.80, for a total value of $263,588.40. Following the completion of the sale, the chief financial officer owned 51,000 shares of the company’s stock, valued at approximately $2,233,800. The trade was a 10.55% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 26,018 shares of company stock valued at $1,113,888. 3.00% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

ELVN has been the topic of a number of recent research reports. HC Wainwright raised their price objective on Enliven Therapeutics from $56.00 to $64.00 and gave the stock a “buy” rating in a research note on Thursday, July 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enliven Therapeutics in a research report on Friday, July 17th. Wall Street Zen raised Enliven Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, May 11th. Mizuho raised their price target on Enliven Therapeutics from $45.00 to $62.00 and gave the stock an “outperform” rating in a research report on Tuesday, June 2nd. Finally, Stifel Nicolaus boosted their price target on Enliven Therapeutics from $60.00 to $80.00 and gave the company a “buy” rating in a research note on Wednesday, July 1st. One equities research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $70.50.

Enliven Therapeutics Stock Down 0.1%

Shares of ELVN stock opened at $52.81 on Friday. Enliven Therapeutics, Inc. has a twelve month low of $14.78 and a twelve month high of $54.88. The stock’s fifty day simple moving average is $45.26 and its 200 day simple moving average is $37.16. The firm has a market capitalization of $3.22 billion, a P/E ratio of -31.62 and a beta of 0.24.

Enliven Therapeutics (NASDAQ:ELVN) last posted its earnings results on Thursday, May 7th. The company reported ($0.38) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.06. As a group, equities research analysts expect that Enliven Therapeutics, Inc. will post -1.57 EPS for the current fiscal year.

Enliven Therapeutics Company Profile

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.